Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Faze Medicines, a biotech focused on neurological diseases, is shutting down

  • Allison DeAngelis

By Allison DeAngelis Nov. 8, 2022

Reprints
Adobe

A biotech company that hoped to use cell biology to address neurological disorders is shutting down.

Faze Medicines was built by VC Third Rock Ventures and launched in 2020 with $81 million from Third Rock, Casdin Capital, and venture funds run by drug giants Novartis, Eli Lilly, and AbbVie.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Allison DeAngelis

Allison DeAngelis

Biotech Startups and Venture Capital Reporter

Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital.

Tags

Create a display name to comment

This name will appear with your comment

Five things I wish I knew earlier in my…
Five things I wish I knew earlier in my journey with chronic pain
‘Three Identical Strangers’: It’s not too late to address…
‘Three Identical Strangers’: It’s not too late to address the ethical violations
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War

Recommended Stories